Clinical utility of a CRTH2 antagonist, OC000459, as an anti-Th2 therapy in atopic dermatitis

A pill already shown to control asthma and hay fever is now being tested to prevent the severe skin flare-ups that define moderate-to-atopic dermatitis. The drug, OC000459, blocks a receptor called CRTH2 found on immune cells that drive allergic inflammation. By stopping these cells from reaching the skin and releasing their inflammatory signals, the treatment aims to prevent disease flares—the main reason patients seek urgent care and the biggest cost to the health service. Current treatments for atopic dermatitis often rely on topical steroids or immunosuppressants, which have limited long-term effectiveness or significant side effects. This study addresses the gap for a safe, oral therapy that can prevent flares before they start. If successful, OC000459 could become a single daily pill that treats not just eczema but also co-existing allergic conditions like asthma and allergic rhinitis, simplifying treatment for patients with multiple allergies. Because the drug targets a mechanism involved in allergic sensitisation, it may also slow or halt the progression of allergic disease over time—the so-called “atopic march” from eczema to asthma. For the NHS, fewer flares mean fewer emergency visits and less reliance on expensive biologic injections.